Called yesterday to see what was happening or if any new news was forth coming. I was told the team was working hard to finalize new money to finish the clinical tested. Hoping to have funding secured here shortly and updates to follow. I asked about what they were thinking the time line is now compared to their model, they are thinking this setback is approx. 4 months worth of time lost so they are thinking late this year clinical should be done most paperwork should be turned over and barring any additional paperwork that could be asked for production should be late this year. talked with Barry Mire. team is doing what they can while in conservation money mode to keep things moving but not as fast if they had full funding
Feel free to call me at the Montreal number below.
Regards,
Barry Mire
Vice-President
RENMARK
FINANCIAL COMMUNICATIONS FINANCIERES
bmire@renmarkfinancial.com
www.renmarkfinancial.com
Follow Renmark on Twitter Renmark LinkedIn Connect With Us
MONTREAL
1050 – 3400 boul. De Maisonneuve O.
Montréal, QC H3Z 3T9
T. 514.939.3989
NEW YORK
26 – 405 Lexington Ave
New York, NY 10174
T. 212.812.7680
ATLANTA
30 – 5 Concourse Pkwy
Atlanta, GA 30328
T. 404.806.1393
TORONTO
1140 – 121 King St. W
Toronto, ON M5H 3T9
T. 416.644.2020
This email message is confidential, may be legally privileged and is intended for the exclusive use of the addressee. If you received this message in error or are not the intended recipient, you should destroy the email message and any attachments or copies, and you are prohibited from retaining, distributing, disclosing or using any information contained. Please inform us of the delivery error by return email. Thank you for your cooperation.
---------- Forwarded message -------
Date: Thu, Jan 31, 2019 at 6:00 AM
Subject: news or update
To: <info@lexingtonbiosciences.com>
Hello
Can you give a current update of where you are at . I am a shareholder and it has been awhile since we have heard where this is at . Thank you for any update you can pass on.
--
Eric Willis
President and Chief Executive Officer
Lexington Biosciences, Inc.
ewillis@lexingtonbiosciences.com
+1 (800) 320-2640
